Loading
A phase 3 trial testing Velzatinib in gastrointestinal stromal tumour, now recruiting.
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (StrateGIST Frontline) is a phase 3 interventional study registered as NCT07585266, led by GlaxoSmithKline, and recruiting on the registry. Official title: A Phase 3, Randomised, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (GIST). Planned enrolment is 800 participants (estimated). The study started in 2026-07-27 and primary completion is expected in 2032-08-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Velzatinib, GSK.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/